Q-omics provides the consensus-scored MRPS18B profile across patient tissues and cancer cell-line models. MRPS18B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPS18B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MRPS18B protein abundance shows 18,354 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where MRPS18B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS18B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS18B survival associations across molecular data types. MRPS18B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS18B RNA expression–survival associations across cancer types. High MRPS18B expression shows unfavorable associations in COAD, LAML and ACC, but favorable associations in KIRC, MESO and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPS18B RNA expression.
This table summarizes MRPS18B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS18B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS18B shows lower tumor expression in KICH and higher tumor expression in STAD, LIHC, BLCA, COAD and KIRP. The KICH box plot shows higher MRPS18B RNA expression in normal versus tumor tissue (log2 FC = −1.685, t-test p < 0.001).
This table shows molecular features associated with MRPS18B in patient tissues and cancer cell lines. In patient samples, MRPS18B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS18B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
